FI963885A0 - Pyrimidiini- tai triatsiinikarboksyylihappojohdannaiset käytettäväksi lääkaineina - Google Patents

Pyrimidiini- tai triatsiinikarboksyylihappojohdannaiset käytettäväksi lääkaineina

Info

Publication number
FI963885A0
FI963885A0 FI963885A FI963885A FI963885A0 FI 963885 A0 FI963885 A0 FI 963885A0 FI 963885 A FI963885 A FI 963885A FI 963885 A FI963885 A FI 963885A FI 963885 A0 FI963885 A0 FI 963885A0
Authority
FI
Finland
Prior art keywords
medicaments
pyrimidine
carboxylic acid
acid derivatives
pct
Prior art date
Application number
FI963885A
Other languages
English (en)
Swedish (sv)
Other versions
FI963885A (fi
FI118589B (fi
Inventor
Ernst Baumann
Uwe Josef Vogelbacher
Joachim Rheinheimer
Dagmar Klinge
Hartmut Riechers
Burkhard Kroeger
Siegfried Bialojan
Claus Bollschweiler
Wolfgang Wernet
Liliane Unger
Manfred Raschack
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of FI963885A0 publication Critical patent/FI963885A0/fi
Publication of FI963885A publication Critical patent/FI963885A/fi
Application granted granted Critical
Publication of FI118589B publication Critical patent/FI118589B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
FI963885A 1994-03-31 1996-09-27 Pyrimidiini- tai triatsiinikarboksyylihappojohdannaiset käytettäväksi lääkeaineina FI118589B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4411225A DE4411225A1 (de) 1994-03-31 1994-03-31 Verwendung von Carbonsäurederivaten als Arzneimittel
DE4411225 1994-03-31
PCT/EP1995/001099 WO1995026716A1 (de) 1994-03-31 1995-03-23 Pyrimidin- oder triazincarbonsäurederivate zur verwendung als arzneimittel
EP9501099 1995-03-23

Publications (3)

Publication Number Publication Date
FI963885A0 true FI963885A0 (fi) 1996-09-27
FI963885A FI963885A (fi) 1996-11-26
FI118589B FI118589B (fi) 2008-01-15

Family

ID=6514334

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963885A FI118589B (fi) 1994-03-31 1996-09-27 Pyrimidiini- tai triatsiinikarboksyylihappojohdannaiset käytettäväksi lääkeaineina

Country Status (28)

Country Link
US (1) US5840722A (fi)
EP (1) EP0752854B1 (fi)
JP (2) JP4001622B2 (fi)
KR (1) KR100365629B1 (fi)
CN (1) CN1070701C (fi)
AT (1) ATE204471T1 (fi)
AU (1) AU695193B2 (fi)
BR (1) BR9507231A (fi)
CA (1) CA2186784C (fi)
CZ (1) CZ290684B6 (fi)
DE (2) DE4411225A1 (fi)
DK (1) DK0752854T3 (fi)
ES (1) ES2162916T3 (fi)
FI (1) FI118589B (fi)
GR (1) GR3036606T3 (fi)
HR (1) HRP950115B1 (fi)
HU (1) HU228063B1 (fi)
IL (1) IL113137A (fi)
NO (1) NO310497B1 (fi)
NZ (1) NZ283333A (fi)
PL (1) PL179580B1 (fi)
PT (1) PT752854E (fi)
RU (1) RU2163808C2 (fi)
SI (1) SI9520048A (fi)
TW (1) TW382594B (fi)
UA (1) UA44734C2 (fi)
WO (1) WO1995026716A1 (fi)
ZA (1) ZA952614B (fi)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel
DE19533023B4 (de) * 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19536891A1 (de) * 1995-10-04 1997-04-10 Basf Ag Neue Aminosäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
DE19726146A1 (de) * 1997-06-19 1998-12-24 Basf Ag Neue ß-Amino und ß-Azidopcarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
SK1522000A3 (en) * 1997-09-04 2000-08-14 Basf Ag Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists
BR9814951A (pt) 1997-10-31 2000-10-03 Basf Ag Derivado de ácido carboxìlico, uso do mesmo, preparação de medicamento para o uso oral, parenteral, combinação, uso de compostos, fragmento estrutural, uso do mesmo, antagonista de receptor de endotelina, e, composto
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
DE19809144A1 (de) * 1998-03-04 1999-09-09 Basf Ag Neue unsymmetrisch substituierte Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶LAMBDA¶/ET¶B¶-Rezeptorantagonisten
DE19809635A1 (de) 1998-03-06 1999-09-09 Basf Ag Verfahren zur Darstellung von Endothelinrezeptorantagonisten vom Sulfanyltyp
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
WO2002064573A1 (de) * 2001-02-14 2002-08-22 Abbott Gmbh & Co. Kg Neue carbonsäurederivate mit alkylsubstituierten triazinen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
EP2118073A2 (en) * 2007-02-02 2009-11-18 Concert Pharmaceuticals Inc. Selective endothelin type-a antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69226813T2 (de) * 1991-06-07 1999-02-18 Ube Industries Pyrimidin- oder Triazin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Herbizide
DE4313412A1 (de) * 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
DE4411225A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verwendung von Carbonsäurederivaten als Arzneimittel

Also Published As

Publication number Publication date
NO964121D0 (no) 1996-09-27
US5840722A (en) 1998-11-24
MX9604448A (es) 1997-07-31
DE4411225A1 (de) 1995-10-05
NO964121L (no) 1996-11-26
CN1070701C (zh) 2001-09-12
JP4001622B2 (ja) 2007-10-31
JPH09510984A (ja) 1997-11-04
DE59509537D1 (de) 2001-09-27
WO1995026716A1 (de) 1995-10-12
TW382594B (en) 2000-02-21
HUT75305A (en) 1997-05-28
GR3036606T3 (en) 2001-12-31
BR9507231A (pt) 1997-09-16
FI963885A (fi) 1996-11-26
IL113137A0 (en) 1995-06-29
PL316563A1 (en) 1997-01-20
ZA952614B (en) 1996-09-30
CA2186784A1 (en) 1995-10-12
NO310497B1 (no) 2001-07-16
ES2162916T3 (es) 2002-01-16
CZ287396A3 (en) 1997-04-16
EP0752854A1 (de) 1997-01-15
DK0752854T3 (da) 2001-10-08
HU228063B1 (en) 2012-09-28
EP0752854B1 (de) 2001-08-22
NZ283333A (en) 1997-02-24
ATE204471T1 (de) 2001-09-15
JP4769742B2 (ja) 2011-09-07
HRP950115A2 (en) 1997-10-31
CN1148807A (zh) 1997-04-30
KR100365629B1 (ko) 2003-04-10
HRP950115B1 (en) 2001-12-31
UA44734C2 (uk) 2002-03-15
FI118589B (fi) 2008-01-15
HU9602695D0 (en) 1996-11-28
KR970702042A (ko) 1997-05-13
IL113137A (en) 1999-10-28
PT752854E (pt) 2002-02-28
CZ290684B6 (cs) 2002-09-11
PL179580B1 (pl) 2000-09-29
AU2135695A (en) 1995-10-23
SI9520048A (en) 1997-02-28
AU695193B2 (en) 1998-08-06
RU2163808C2 (ru) 2001-03-10
JP2007131645A (ja) 2007-05-31
CA2186784C (en) 2007-02-20

Similar Documents

Publication Publication Date Title
FI963885A (fi) Pyrimidiini- tai triatsiinikarboksyylihappojohdannaiset käytettäväksi lääkaineina
ES2102195T3 (es) Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides.
DK0778834T3 (da) Bicykliske, heterocykliske diarylforbindelser som inhibitorer af cyclooxygenase-2
TR199800585T2 (xx) COX-2 �nhibit�rleri Olarak (Metils�lfonil)Fenil-2-(5H)-Furanonlar.
DK0678089T3 (da) N-Acylpyrrolidiner og lægemidler til behandling eller forebyggelse af cholecystokinin- og gastrin-relaterede forstyrrelser
BR9610175A (pt) Composto processo de preparação do composto composição farmacêutica e utilização do composto
MX9304403A (es) Derivados farmacologicamente activos de ó-(aminometilo terciario)-bencenmetanol
MY113529A (en) New derivatives of imidazole n- benzyldioxole,processes for their preparation, their use as medicaments and pharmaceutical compositions containing them
BR9611572A (pt) Produção de um sal de ácido clavulânico
AU6759587A (en) 5-monoaryl-3-AS-triazinones substituted at the 2-position, the process for preparing them and their application as medicinal products
ES2099973T3 (es) Derivados de ureido-acetamida su preparacion y los medicamentos que los contienen.
ES2116528T3 (es) Nuevo compuesto, la leustroducsina h, su preparacion y su utilizacion terapeutica.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118589

Country of ref document: FI

PC Transfer of assignment of patent

Owner name: ABBVIE DEUTSCHLAND GMBH & CO KG

MA Patent expired